Phytopharm well-funded as it invests in neurodegenerative pipeline
This article was originally published in Scrip
Executive Summary
Phytopharm says its three year cash runway will see it through to the end of a recently initiated Phase II trial in early-stage Parkinson's disease with lead candidate Cogane plus ready two other programmes to enter clinical testing.